Aligos Therapeutics (ALGS) Share-based Compensation (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Share-based Compensation for 8 consecutive years, with $2.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 84.19% year-over-year to $2.1 million; the trailing twelve-month figure through Jun 2026 stood at $2.1 million (down 71.46% YoY), and the FY2025 full-year result was $11.4 million, up 34.88% from the prior year.
• Share-based Compensation improved to $2.1 million in Q2 2026 per ALGS's latest filing, from $2.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $11.1 million in Q3 2023 and bottomed at $1.0 million in Q1 2025.
• Historically, Share-based Compensation has averaged $5.6 million across 5 years, with a median of $3.0 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation tumbled 90.02% in 2025, then soared 108.78% in 2026.
• Over 5 years, Share-based Compensation stood at $3.4 million in 2022, then decreased by 24.39% to $2.6 million in 2023, then tumbled by 33.99% to $1.7 million in 2024, then decreased by 14.49% to $1.5 million in 2025, then soared by 46.67% to $2.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2.1 million, $2.1 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.